.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BB09_Gliclazide.Gliclazide .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BB09_Gliclazide.Gliclazide| name: | Gliclazide |
| ATC code: | A10BB09 | route: | oral |
| n-compartments | 1 |
Gliclazide is a second-generation sulfonylurea antidiabetic drug that stimulates insulin secretion from pancreatic beta cells. It is used orally for the management of type 2 diabetes mellitus and is approved for use in many countries.
Pharmacokinetic parameters in healthy adult volunteers after single oral 80 mg dose.
Shaik, M, et al., & Kilari, EK (2018). Population pharmacokinetics of gliclazide in normal and diabetic rabbits. Biopharmaceutics & drug disposition 39(5) 265–274. DOI:10.1002/bdd.2132 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29679474
Adiwidjaja, J, & Sasongko, L (2021). Effect of Nigella sativa oil on pharmacokinetics and pharmacodynamics of gliclazide in rats. Biopharmaceutics & drug disposition 42(8) 359–371. DOI:10.1002/bdd.2300 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34327715
Davis, TM, et al., & Barrett, PH (2000). Pharmacokinetics and pharmacodynamics of gliclazide in Caucasians and Australian Aborigines with type 2 diabetes. British journal of clinical pharmacology 49(3) 223–230. DOI:10.1046/j.1365-2125.2000.00162.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/10718777